Immunomodulatory properties of anticancer monoclonal antibodies: is the ‘magic bullet’ still a reliable paradigm?
- 1 January 2011
- journal article
- editorial
- Published by Future Medicine Ltd in Immunotherapy
- Vol. 3 (1), 1-4
- https://doi.org/10.2217/imt.10.92
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Divergent Intracellular Sorting of FcγRIIA and FcγRIIB2*Online Journal of Public Health Informatics, 2010
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and ImmunoescapeJournal of Clinical Oncology, 2010
- Biomarker-Based Prediction of Response to Therapy for Colorectal CancerAmerican Journal of Clinical Pathology, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Colorectal cancer in review: the role of the EGFR pathwayExpert Opinion on Investigational Drugs, 2010
- Immunotherapy of Malignant Disease with Tumor Antigen–Specific Monoclonal AntibodiesClinical Cancer Research, 2010
- Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytesBritish Journal of Cancer, 2009
- Roles of TNF-α gene polymorphisms in the occurrence and progress of SARS-Cov infection: A case-control studyBMC Infectious Diseases, 2008
- Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functionsJCI Insight, 2005
- Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic CellsThe Journal of Experimental Medicine, 2002